Stock Research for ARTH

ARTH
Current Price

$0.3200


Latest Update: 2018-02-20 16:00:00

High
$ 0.3200
Low
$ 0.3151
Close
$ 0.3200
Volume
76691
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

ARTH Stock Chart & Research Data

The ARTH chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ARTH chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ARTH Due diligence Resources & Stock Charts

The ARTH stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ARTH Detailed Price Forecast - CNN Money CNN View ARTH Detailed Summary - Google Finance
Yahoo View ARTH Detailed Summary - Yahoo! Finance Zacks View ARTH Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ARTH Trends & Analysis - Trade-Ideas Barrons View ARTH Major Holders - Barrons
NASDAQ View ARTH Call Transcripts - NASDAQ Seeking View ARTH Breaking News & Analysis - Seeking Alpha
Spotlight View ARTH Annual Report - CompanySpotlight.com OTC Report View ARTH OTC Short Report - OTCShortReport.com
TradeKing View ARTH Fundamentals - TradeKing Charts View ARTH SEC Filings - Bar Chart
WSJ View Historical Prices for ARTH - The WSJ Morningstar View Performance/Total Return for ARTH - Morningstar
MarketWatch View the Analyst Estimates for ARTH - MarketWatch CNBC View the Earnings History for ARTH - CNBC
StockMarketWatch View the ARTH Earnings - StockMarketWatch MacroAxis View ARTH Buy or Sell Recommendations - MacroAxis
Bullish View the ARTH Bullish Patterns - American Bulls Short Pains View ARTH Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ARTH Stock Mentions - StockTwits PennyStocks View ARTH Stock Mentions - PennyStockTweets
Twitter View ARTH Stock Mentions - Twitter Invest Hub View ARTH Investment Forum News - Investor Hub
Yahoo View ARTH Stock Mentions - Yahoo! Message Board Seeking Alpha View ARTH Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for ARTH - SECform4.com Insider Cow View Insider Transactions for ARTH - Insider Cow
CNBC View ARTH Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ARTH - OTC Markets
Yahoo View Insider Transactions for ARTH - Yahoo! Finance NASDAQ View Institutional Holdings for ARTH - NASDAQ


Stock Charts

FinViz View ARTH Stock Insight & Charts - FinViz.com StockCharts View ARTH Investment Charts - StockCharts.com
BarChart View ARTH Stock Overview & Charts - BarChart Trading View View ARTH User Generated Charts - Trading View


Latest Financial News for ARTH

Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application
Posted on Monday February 05, 2018

FRAMINGHAM, Mass., Feb. 05, 2018-- Positive data from a clinical study of patients undergoing dermatologic surgery and treated with the AC5™ was published in the peer-reviewed journal Dermatologic Surgery, ...


Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January 8th, 2018
Posted on Tuesday January 02, 2018

FRAMINGHAM, Mass., Jan. 02, 2018-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at The 10 th Annual Biotech ...


Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
Posted on Monday December 18, 2017

FRAMINGHAM, Mass., Dec. 18, 2017-- Arch Therapeutics, Inc., developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company has withdrawn its 510 notification ...


Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
Posted on Tuesday July 25, 2017

Arch Therapeutics, Inc. , developer of novel liquid, gel and solid hemostatic and wound care devices, today announced that the Company made a 510 submission to the U.S. Food and Drug Administration for ...


Arch Therapeutics Inc.
MarketWatch - Apr 5, 2017
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development of novel approach to stop bleeding, control leaking, and manage wounds during surgery, trauma, and interventional care.

Tiny Arch Therapeutics Just Doubled: Time To Dump?
Seeking Alpha - Apr 11, 2016
Arch Therapeutics, Inc. (OTCQB:ARTH) is a tiny Boston area developmental biotech company that has developed what the company calls a "novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care.

Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman ...
GlobeNewswire (press release) - Sep 6, 2017
FRAMINGHAM, Mass., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a presenting company at the 19th ...

Arch Therapeutics (ARTH) Lifted to “Buy” at Zacks Investment Research
StockNewsTimes - 7 hours ago
Arch Therapeutics (OTCMKTS:ARTH) was upgraded by Zacks Investment Research from a “sell” rating to a “buy” rating in a report released on Tuesday.

Enter a stock symbol to view the stock details.